Advanced Therapy Medicines Based on Oncolytic Viruses (Part II: Development and Authorisation of IMLYGIC®)
The only oncolytic virus-based product authorised in the US and EU—IMLYGIC®, a genetically modified herpes simplex virus type 1 (by BioVex Inc., a subsidiary of Amgen, Inc.)—was developed and approved for clinical use as monotherapy for recurrent unresectable melanoma. The aim of the study was to an...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado em: |
Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
2021-12-01
|
| coleção: | Регуляторные исследования и экспертиза лекарственных средств |
| Assuntos: | |
| Acesso em linha: | https://www.vedomostincesmp.ru/jour/article/view/382 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|